Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
2359.HK
603259.SHG
After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order
China’s leading provider of outsourced medical services said its profit and revenue rose 48.4% and 30% last year, respectively, marking a significant slowdown from the previous yearKey Takeaways:WuXi Biologics revenue…
FAST NEWS: Wuxi Bio Dives after Major Stakeholder Sells Shares
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Tuesday that Biologics Holdings, one of its substantial shareholders controlled by its Chairman Li Ge, sold 56…
Buoyed by Bumper Profits, WuXi Biologics Seeks to Bolster Global Supply Chain
Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would…
